Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Genmont Biotech Incorporation is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. Each of these 3 pending office actions is assigned to a different person among 3 distinct examiners, resulting in a decentralized prosecution process. The applications are also located in 3 distinct art units, indicating that the company's current intellectual property efforts are spread across different technical focuses within the Biotechnology & Pharmaceuticals field.
DAVIS, RUTH A is listed as the busiest examiner, but she is responsible for 1 pending office action. Because there are 3 distinct examiners and 3 distinct art units for the current workload, there is no opportunity for examiner-specific or unit-specific synergy. Practitioners must handle each of the 3 pending office actions as an isolated case, as the rules and preferences of the various art units will likely vary. This distribution highlights a specialized portfolio where each application represents a unique technical challenge. The 1 pending office action per examiner indicates that no single official has a broad view of the company's current filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, RUTH A | 1 | 60.9% | +31.0% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17862766 | COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST | DURYEE, ALEXANDER MARSH | 37d overdue |
| 19562301 | USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY | DAVIS, RUTH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17862766 | COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST | DURYEE, ALEXANDER MARSH | 37d overdue |
| 19562301 | USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY | DAVIS, RUTH A | — |
| 18585638 | USE OF LACTOBACILLUS PARACASEI GM-080 AND PEPTIDES THEREOF FOR ANTIMICROBIA | NIEBAUER, RONALD T | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1658 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19562301 | USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY | DAVIS, RUTH A | 1699 | §102§112Other | Non-Final OA | — | Pending | Mar 10, 2026 |
| 18585638 | USE OF LACTOBACILLUS PARACASEI GM-080 AND PEPTIDES THEREOF FOR ANTIMICROBIA | NIEBAUER, RONALD T | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 17862766 | COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST | DURYEE, ALEXANDER MARSH | 1657 | §103§112 | Non-Final OA | 37d overdue | Pending | Jul 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenmont Biotech Incorporation has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Ruth A Davis has the most, with 1 of Genmont Biotech Incorporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
